Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce (CELG-RI) Stock Overview
Explore Bristol-Myers Squibb Company Ce’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
84.1B
P/E Ratio
17.40
EPS (TTM)
N/A
ROE
0.32%
CELG-RI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company Ce (CELG-RI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.40 and a market capitalization of 84.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
34,100
Princeton, DE
1970